- |||||||||| furosemide / Generic mfg.
Journal: Assessing anti-doping knowledge among Taiwanese pharmacists. (Pubmed Central) - Oct 28, 2023
The dosing regimens of narrow therapeutic window OAT drug substrates may need to be adjusted during inflammatory conditions. This study highlights the heterogeneity of anti-doping knowledge among pharmacy professionals and provides practical relevance in organising future educational topics and research-based activities.
- |||||||||| garsorasib (D-1553) / InventisBio
New P1 trial: A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 (clinicaltrials.gov) - Oct 27, 2023
P1, N=44, Active, not recruiting,
- |||||||||| furosemide / Generic mfg.
Journal: Dysregulation of the WNK4-SPAK/OSR1 pathway has a minor effect on baseline NKCC2 phosphorylation. (Pubmed Central) - Oct 26, 2023
The WNK4-SPAK/OSR1 pathway mediates activating phosphorylation of the furosemide-sensitive Na-K-2Cl cotransporter (NKCC2) and the thiazide-sensitive NaCl cotransporter (NCC)...Our data show that disruption of the WNK4-SPAK/OSR1 pathway only mildly affects NKCC2 phosphorylation, suggesting a role for other kinases in NKCC2 activation. In FHHt models NKCC2 phosphorylation is unchanged despite higher WNK4 abundance, explaining the thiazide-sensitivity of FHHt.
- |||||||||| furosemide / Generic mfg.
Journal: Prevention of Contrast-induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention. (Pubmed Central) - Oct 25, 2023
In patients at high risk for CIN, additional contrast-sparing strategies may be applied, such as using a contrast reduction system, 5 Fr catheter with no sideholes, CM dilution, limiting test injection, confirming placement using guidewire, use of stent enhancing imaging technology, using metallic/software roadmap to guide PCI, use of IVUS or dextran-based OCT, and coronary aspiration. A more advanced hydration technique based on central venous pressure, left ventricular end-diastolic pressure, or using furosemide-matched hydration, might be considered.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Checkpoint inhibition: An unusual case of checkpoint-inhibitor-induced pleuropericarditis. (Pubmed Central) - Oct 23, 2023
Cinacalcet therapy can be used successfully in the treatment of individuals with FHH. Clinicians should recognize these potential immune-mediated adverse effects to provide effective and timely management and optimize patient care.
- |||||||||| furosemide / Generic mfg.
Biomarker, Review, Journal: An update on the role of fluid overload in the prediction of outcome in acute kidney injury. (Pubmed Central) - Oct 20, 2023
This review will also provide detailed descriptions of future directions and the changing paradigms around fluid balance and AKI in critical care nephrology, including the incorporation of the sequential utilization of risk stratification, novel biomarkers, and functional kidney tests (furosemide stress test) into research and ultimately clinical care. Finally, the review will conclude with novel methods currently under study to assess fluid balance and distribution (point of care ultrasound and bioimpedance).
- |||||||||| ceftriaxone / Generic mfg., furosemide / Generic mfg.
Journal: Sonographic Detection of Fetal Cholelithiasis. (Pubmed Central) - Sep 28, 2023
If complications occur or if the gallstones persist after birth, further evaluation and management may be necessary. Treatment options can include medication, minimally invasive procedures, or, in severe cases, surgical removal of the gallbladder.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. (Pubmed Central) - Sep 16, 2023
Despite this, GFR did not differ between the groups at discharge (51 [41; 66] ml/min/1.73 m2 and 49 [38; 67] ml/min/1.73 m2, respectively; p = 0.84). In the dapagliflozin group, frequency of AKI episodes was not increased compared to the control group (13 and 9.4%, respectively; p = 0.45).Conclusion
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. (Pubmed Central) - Sep 15, 2023
Despite this, GFR did not differ between the groups at discharge (51 [41; 66] ml/min/1.73 m2 and 49 [38; 67] ml/min/1.73 m2, respectively; p = 0.84). In the dapagliflozin group, frequency of AKI episodes was not increased compared to the control group (13 and 9.4%, respectively; p = 0.45).Conclusion
- |||||||||| Intradermal Testing to Minimize Recurrence Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (Monitor 02) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_735;
As her oncologist wished to continue platinum agent chemotherapy, we assessed if cisplatin contributed to DRESS and if carboplatin could be used...Optimal intradermal test concentrations are often unclear, and cross-reactivity among platinum agents for delayed hypersensitivity reactions is not well known. This case highlights the potential utility of intradermal testing to distinguish between platinum agents in DRESS.
- |||||||||| furosemide / Generic mfg.
Journal: Etiology and prognosis of nephrocalcinosis according to gestational age in Korean children. (Pubmed Central) - Sep 13, 2023
This case highlights the potential utility of intradermal testing to distinguish between platinum agents in DRESS. While the overall outcomes of pediatric NC are favorable, underlying monogenic causes should be studied, especially in full-term patients without known clinical risk factors.
- |||||||||| furosemide / Generic mfg.
Trial completion date: Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP (clinicaltrials.gov) - Sep 13, 2023
P3, N=138, Recruiting,
While the overall outcomes of pediatric NC are favorable, underlying monogenic causes should be studied, especially in full-term patients without known clinical risk factors. Trial completion date: Aug 2023 --> Aug 2024
- |||||||||| Oxbryta (voxelotor) / Pfizer
Enrollment closed, Enrollment change: Voxelotor CYP and Transporter Cocktail Interaction Study (clinicaltrials.gov) - Sep 13, 2023
P1, N=18, Active, not recruiting,
Trial completion date: Aug 2023 --> Aug 2024 Recruiting --> Active, not recruiting | N=46 --> 18
- |||||||||| furosemide / Generic mfg.
Preclinical, Journal: Long-term survival of LGR5 expressing supporting cells after severe ototoxic trauma in the adult mouse cochlea. (Pubmed Central) - Sep 11, 2023
P30 animals were deafened with a single dose of furosemide and kanamycin...The presence of LGR5+ SCs in the adult mouse cochlea, which persists after severe HC loss, suggests potential regenerative capacity of endogenous cochlear progenitor cells in adulthood. To our knowledge, this is the first study showing not only long-term survival of LGR5+ SCs in the normal and ototoxically damaged cochlea, but also increased Lgr5 expression in the adult mouse cochlea after deafening, suggesting long-term availability of potential target cells for future regenerative therapies.
- |||||||||| furosemide / Generic mfg.
Journal: Study of Auditory Brainstem Evoked Response at Varying Frequencies in Subclinical Hypothyroid Subjects. (Pubmed Central) - Sep 11, 2023
To our knowledge, this is the first study showing not only long-term survival of LGR5+ SCs in the normal and ototoxically damaged cochlea, but also increased Lgr5 expression in the adult mouse cochlea after deafening, suggesting long-term availability of potential target cells for future regenerative therapies. Those on epileptic, neuroleptics, depression, psychosis drugs, inflammatory, proliferative, traumatic ear disorder, smokers, on tobacco, COVID-19 positive subjects, altered sensorium, drug abuse, diabetes mellitus, neuropathy, hypertension, cardiac arrhythmia, family history of hearing disorder, and furosemide drug were excluded...Mean
- |||||||||| acetazolamide / Generic mfg., furosemide / Generic mfg.
Journal: Secondary Intracranial Hypertension in Pediatric Lyme Meningitis. (Pubmed Central) - Sep 11, 2023
Final visual acuity was 20/20 in each eye of all patients, suggesting that a titrated approach to therapy depending on the severity of presentation can result in good visual outcomes in these cases. Additionally, symptoms can recur after medication wean, so patients should be monitored closely with any discontinuation of intracranial pressure lowering medications.
- |||||||||| bortezomib / Generic mfg.
Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma (In Person) - Sep 10, 2023 - Abstract #IMW2023IMW_604;
It was found that NH4+ can upregulate the expression of NEK2, and NH4+ can increase the acetylation of NEK2 and reduce its ubiquitin degradation, thus maintaining its protein stability.SLC12A2 as the key transmembrane transporter that mediates the uptake of NH4+ by MM cells, we discovered that furosemide sodium (Fus) can downregulate the expression of SLC12A2 in MM cells. In summary, we identify, for the first time, CFr and NH4+ as key modulators of MM relapse, unveil novel molecular mechanisms for drug resistance in MM patients, and provide new therapeutic strategies for the intervention of MM progression and drug resistance.
- |||||||||| furosemide / Generic mfg.
Journal: Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool. (Pubmed Central) - Sep 7, 2023
Careful consideration of factors such as dosage, concurrent medication use, and renal function of the patient is necessary for clinical practice when using furosemide. Our practical prognostic model for HA-AKI associated with furosemide use can be utilized to assist clinicians in making informed decisions about patient care and treatment.
- |||||||||| furosemide / Generic mfg.
Journal: Enhanced Photothermal Activity of Nanoconjugated (Pubmed Central) - Aug 31, 2023
The photothermal property of COF@PBNCs is further used in the construction of immunosensor for the detection of furosemide (FUR). With the help of handheld thermal imager, the concentration of FUR can be easily read, thus shedding a new light in the construction of visual sensor for simple and low-cost point-of-care testing.
- |||||||||| furosemide / Generic mfg.
Trial completion date, Trial primary completion date: PURE: Peritoneal Ultrafiltration in Cardio Renal Syndrome. (clinicaltrials.gov) - Aug 30, 2023
P1/2, N=84, Not yet recruiting,
With the help of handheld thermal imager, the concentration of FUR can be easily read, thus shedding a new light in the construction of visual sensor for simple and low-cost point-of-care testing. Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
- |||||||||| digoxin / Generic mfg., furosemide / Generic mfg.
A rapid review of efficacy and pain infliction among newest treatment modalities for cutaneous viral warts (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3090;
Intralesional Vitamin D had the highest efficacy rate and is therefore a very promising alternative to current destructive treatment modalities and furthermore has also the advantage of targeting multiple distant viral warts. Photodynamic therapy using Eosin-Trans had the highest efficacy together with least pain, which is very practical for the treatment of children, which are the main patient population.
- |||||||||| furosemide / Generic mfg.
Journal, HEOR: Reduced heart (Pubmed Central) - Aug 23, 2023
Patients at-risk of early repeat hospitalization for fluid overload may be identified using these risk factors for targeted interventions. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p
- |||||||||| furosemide / Generic mfg.
There Might Be Harm, When You Hear the Alarm! Noncardiogenic Pulmonary Edema During Hysteroscopic Surgery (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_3966;
The most likely cause of fluid overload, oxygen desaturation, and EKG changes was noncardiogenic pulmonary edema resulting from vascular sinus absorption of fluids used during hysteroscopic surgery. Consistent communication between all clinical providers regarding volume of infusion fluid and vital sign changes is important in maintaining optimal patient care.
- |||||||||| Biomarker, Trial completion, Trial completion date: Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters (clinicaltrials.gov) - Aug 16, 2023
P1, N=32, Completed,
Consistent communication between all clinical providers regarding volume of infusion fluid and vital sign changes is important in maintaining optimal patient care. Recruiting --> Completed | Trial completion date: Jun 2024 --> Jul 2023
- |||||||||| furosemide / Generic mfg.
Trial termination: FaST-1: Furosemide as Supportive Therapy for COVID-19 Respiratory Failure (clinicaltrials.gov) - Aug 15, 2023
P2/3, N=40, Terminated,
Recruiting --> Completed | Trial completion date: Jun 2024 --> Jul 2023 Active, not recruiting --> Terminated; Lack of recruitment due to decline in critically ill Covid-19 patients
- |||||||||| furosemide / Generic mfg.
Trial completion date, Trial primary completion date: Testing of an Electronic Patch During Mild Dehydration (clinicaltrials.gov) - Aug 15, 2023
P=N/A, N=35, Recruiting,
Active, not recruiting --> Terminated; Lack of recruitment due to decline in critically ill Covid-19 patients Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Dec 2024
|
